917396-39-5Relevant articles and documents
Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration
Matsufuji, Tetsuyoshi,Shimada, Kousei,Kobayashi, Shozo,Kawamura, Asuka,Fujimoto, Teppei,Arita, Tsuyoshi,Hara, Takashi,Konishi, Masahiro,Abe-Ohya, Rie,Izumi, Masanori,Sogawa, Yoshitaka,Nagai, Youko,Yoshida, Kazuhiro,Takahashi, Hisashi
, p. 750 - 755 (2014)
The discovery and optimization of a novel series of BRS-3 agonists are described. We explored a potent BRS-3 agonist with low brain penetration to avoid an adverse effect derived from central nervous system exposure. Through the derivatization process, chiral diazepines 9f and 9g were identified as possessing low brain penetration as well as potent in vitro activity against human and mouse BRS-3s.
HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS
-
Paragraph 112; 177-178, (2021/08/27)
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.
COMPOUNDS WITH NEMATICIDAL ACTIVITY
-
, (2013/05/22)
The present invention relates to the use of known pyridyl carboxamide derivatives and novel pyridyl carboxamide derivatives as nematicides, compositions containing such compounds and methods for the control of nematodes.